China, People's Republic of INTRODUCTION AND OBJECTIVES: Adrenocortical carcinoma (ACC) is a rare malignancy characterized with poor survival at advanced and metastatic stage, with no curative treatment available. CTNNB1 is frequently mutated in ACC and is identified as one of the driver mutations. Current targeted therapy for CTNNB1 in ACC is lacking and our study aims to screening for effective agents with antineoplastic activity against ACC with CTNNB1 mutation.
INTRODUCTION AND OBJECTIVES: Adrenocortical carcinoma (ACC) is a rare malignancy characterized with poor survival at advanced and metastatic stage, with no curative treatment available. CTNNB1 is frequently mutated in ACC and is identified as one of the driver mutations. Current targeted therapy for CTNNB1 in ACC is lacking and our study aims to screening for effective agents with antineoplastic activity against ACC with CTNNB1 mutation.
METHODS: In silico screening of the Genomics of Drug Sensitivity in Cancer (GDSC) database that included drug sensitivity data of 265 compounds in 1,074 cancer cells were conducted. Drug sensitivity in cells with CTNNB1 mutation was analyzed, and further in vitro and in vivo studies were performed using the compound.
RESULTS: Only one compound, Nutlin-3a, an MDM2 inhibitor was significantly sensitive in 18 cancer cells with CTNNB1 mutation. However, mutation of TP53, which was also common in ACC conferred significant resistance to Nutlin-3a. Further analysis of the 18 cells revealed no significant efficacy between cells with both CTNNB1 and TP53 mutation indicating concomitant TP53 mutation did not impact on drug efficacy. We verified Nutilin-3a-inhibited cellular proliferation in ACC cell line NCI-H295R which harbored CTNNB1 mutation but not in SW13 cells which did not. Nutlin-3a induced cell apoptosis and G1 cellcycle arrest in NCI-H295R cells. Nutlin-3a also decreased cellular migration and inhibited epithelial-to-mesenchymal transition (EMT) process in terms of EMT index. Moreover, Nutlin-3a resulted in decreased beta-Catenin level independent of p53 level in NCI-H295R but not SW13 cells. We also evaluated the effect of Nutlin-3a on hormonal secretion of NCI-H295R cells and found it resulted in decreased levels of cortisol, androgen, and progesterone. Nutlin-3a treatment inhibited ACC tumor growth and hormonal secretion with no observed toxicity in mice in vivo.
CONCLUSIONS: Our study revealed Nutlin-3a, the first-generation MDM2 inhibitor potently inhibited ACC with CTNNB1 mutation. Several new derivatives of Nutlin-3a has now entered clinical trials, holding promise for targeted MDM2 inhibition in CTNNB1-mutant ACC. However, how p53/MDM2 axis coordinate with Wnt/beta-Catenin signaling in ACC warrants further study.
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MP37-03 LEVEL OF PRENATAL ADRENAL STEROIDS HORMONES AFFECTS BODY WEIGHT AT BIRTH
Takahiko Mitsui*, Chuo-city, Japan; Atsuko Araki, Sachiko Ito, Chihiro Miyashita, Kimihiko Moriya, Takeya Kitta, Kazutoshi Cho, Keita Morioka, Nobuo Shinohara, Sapporo, Japan; Masayuki Takeda, Chuo-city, Japan; Reiko Kishi, Sapporo, Japan; Katsuya Nonomura, Kushiro, Japan INTRODUCTION AND OBJECTIVES: It is well known that prenatal environment affects infant development and prenatal stress has a negative impact on their child outcomes. The hypothalamic-pituitary-adrenal (HPA) axis is one of the major systems involved in stress response and its regulation. In fact, maternal cortisol also can pass through the placenta and affect fetal cortisol level and HPA development. In the present study, we investigated relationship between steroids levels in cord blood and body weight at birth.
METHODS: Of 514 who participated in a prospective cohort study of birth in Sapporo, the following steroid hormone levels in 294 stored cord blood (135 boys and 159 girls) were measured; estradiol (E), testosterone (T), progesterone (P), androstenedione (4-dione), dehydroepiandrosterone (DHEA), cortisol and cortisone. Information of birth weight obtained from medical records at birth. The relationship between birth weight and steroid hormone levels in cord blood samples was calculated using a multiple linear regression analysis. The inclusion of covariates was based on biological considerations and adjustments were made for gestational age, maternal smoking and alcohol consumption during pregnancy, and body weight of parents. Significance levels were set to 0.05 for all comparisons.
RESULTS: The median concentrations of T and T/E were significantly higher in males than in females, while the median concentration of DHEA was significantly higher in females. There was a trend that birth weight was heavier in boys than in girls. Mother's weight before pregnancy, not father's weight, significantly affected birth weight of their children. Regarding the hormone levels of P, Cortisone, 4-Dion/ DHEA and Cortisone/Cortisol in cord blood, there was significant relationship with birth weight in boys, not in girls (Table) .
CONCLUSIONS: The present study indicated that prenatal adrenal steroids affected body weight at birth. Further, 4-Dion/DHEA and Cortisol/Cortisone indicate activity of 3b-hydrosteroid dehydrogenase 11b-hydrosteroid dehydrogenase type 2, respectively. Thus, in addition to adrenal steroid hormones, converting enzymes such as 11b-hydrosteroid dehydrogenase type 2 and 3b-hydrosteroid dehydrogenase in the placenta and fetal adrenal gland may also have impact on birth weight in boys. Masayuki Tasaki*, Takashi Kasahara, Itsuhiro Takizawa, Vladimir Bilim, Kazuhide Saito, Tsutomu Nishiyama, Yoshihiko Tomita, Niigata, Japan INTRODUCTION AND OBJECTIVES: Most adrenal incidentalomas are nonfunctioning cortical adenomas which do not cause classical clinical signs and symptoms of hormone excess syndromes. The optimal frequency and duration of follow-up for patients who have nonfunctioning adrenal incidentalomas are uncertain. The aim of this study was to investigate the value of long-term radiological and hormonal follow-up in the patients with nonfunctioning adrenal incidentalomas. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e475
